Analystreport

Ignyta, Inc. (NASDAQ: RXDX) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock.

Prometheus Biosciences, Inc.  (RXDX) 
Last prometheus biosciences, inc. earnings: 11/7 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ignyta.com